Results 211 to 220 of about 440,067 (322)

Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

open access: green, 1993
Stephen L. Dewey   +8 more
openalex   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran   +10 more
wiley   +1 more source

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Brain Metastasis of Various Tumors Using Positron Emission Tomography? [PDF]

open access: yesCancers (Basel)
Arslan E   +8 more
europepmc   +1 more source

A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography

open access: bronze, 1990
Éric Salmon   +7 more
openalex   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

open access: yesESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu   +22 more
wiley   +1 more source

Methodological Aspects of Brain Activation Studies: Cerebral Blood Flow Determined with [15O]Butanol and Positron Emission Tomography

open access: bronze, 1994
Martin Ingvar   +7 more
openalex   +1 more source

Re‐PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy